Lynx Therapeutics Overview
Founded
1992
Status
Acquired/Merged
Latest Deal Type
M&A
Financing Rounds
7
Lynx Therapeutics General Information
Description
Developer of genetic analysis technologies for pharmaceutical, biotechnology and agricultural industries. The company's cloning and sequencing technologies provide comprehensive and quantitative digital gene expression data which is important to systems biology research enabling drug discovery and development companies to research, develop and implement new treatments for improving human health.
Contact Information
Website
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Primary Office
- 25861 Industrial Boulevard
- Hayward, CA 94545
- United States
Lynx Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Lynx Therapeutics‘s full profile, request access.
Request a free trial
Lynx Therapeutics Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Kevin Corcoran | Board Member, President & Chief Executive Officer |
Lynx Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Lynx Therapeutics‘s full profile, request access.
Request a free trial